QRxPharma wins US patent for opioid compounds
QRxPharma (ASX:QRX) has received a US patent covering the development of hybrid opioid compounds.
The patent encompasses a hybrid morphine-oxycodone molecule, where the two opioids are chemically linked. The patent expires in 2031.
QRxPharma is seeking US FDA approval for MoxDuo, a formulation consisting of morphine and oxycodone in the same tablet, and expects a decision on the immediate-release version shortly.
The company already holds a US patent covering the use of morphine and oxycodone in the same capsule, granting protection for both the immediate- and controlled-release versions through to 2023.
But the new patent covers chemically linking the two opioids to form a new composition of matter more potent than they would be if administered separately.
QRxPharma CEO Dr John Haloday said the new patent “protects next-generation dual-opioid combination products that are chemically unique”.
The company has licensed MoxDuo IR to Actavis in a deal worth up to US$150 million ($158.9 million).
QRxPharma shares were trading unchanged at $1.19 as of around 1 pm on Thursday.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
